Saturday, July 11, 2026

Drug profile · INN

glecaprevir + pibrentasvir

glecaprevir + pibrentasvir (MAVIRET) is an FDA-listed pharmaceutical active ingredient. Associated with AbbVie.

TGA: approved
Patents linked 1
Pipeline programs 1
News articles 0
Drug details — glecaprevir + pibrentasvir

Quick answer

glecaprevir + pibrentasvir (MAVIRET) is an FDA-listed pharmaceutical active ingredient. Associated with AbbVie.

Key facts

INN glecaprevir + pibrentasvir
Brand MAVIRET
Originator AbbVie

Approval history

Authority Status Date
TGA approved

Pipeline programs

  1. Glecaprevir/Pibrentasvir Phase 3 · AbbVie · Hepatitis C Virus (HCV)
  1. US 8648037

    Macrocyclic proline derived HCV serine protease inhibitors

    Expires 2034-02-06T00:00:00.000Z

    granted

Frequently asked questions

What is glecaprevir + pibrentasvir?

glecaprevir + pibrentasvir (MAVIRET) is an FDA-listed pharmaceutical active ingredient. Associated with AbbVie.

What is the brand name for glecaprevir + pibrentasvir?

MAVIRET is a marketed brand name for glecaprevir + pibrentasvir. Check FDA Drugs@FDA for the current US label holder and prescribing information.